So what do you think has fundamentally changed for the company for it to become cashflow positive?
The company isn't even sure that this latest capital raise will see them become cashflow positive and they burnt through 30million from ipo, 12m from cap raise 2018, 11m 2019 and 3m end 2019, 5m 2020.
The product has been on the market since 2015 and management hasn't changed despite the failures.
Like the concept of the product and that revenue has increased with low EV but the product is not exactly new if it has been available for 6 years so it seems to be more a marketing problem or people don't actually want the product. Better clinical data seems like a good step to help with marketing but timelines are more than a year for that.
So what do you think has fundamentally changed for the company...
Add VTI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.257M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 1429 | 1 |
View Market Depth
| Last trade - 16.12pm 03/05/2024 (20 minute delay) ? |
| VTI (ASX) Chart |
Day chart unavailable